CoLucid Pharmaceuticals Inc

Type: Company
Name: CoLucid Pharmaceuticals Inc
First reported Apr 15 2014 - Updated Apr 16 2014 - 1 reports

New Market Research Report: Alzheimer's Disease - Pipeline Review, H1 2014

Boston, MA -- ( SBWIRE ) -- 04/15/2014 -- Global Markets Direct's, 'Alzheimer's Disease - Pipeline Review, H1 2014', provides an overview of the Alzheimer's Disease's therapeutic pipeline.This report provides comprehensive information on the therapeutic ... [Published SBWire - Apr 15 2014]
First reported Mar 13 2014 - Updated Mar 13 2014 - 1 reports

Modest growth forecast for global migraine market to 2023

The global migraine treatment market value is expected to undergo a modest increase over the coming years, climbing from $2.5 billion in 2012 to $3.7 billion by 2023, at a compound annual growth rate (CAGR) of 3.6%.According to a new report from research ... [Published Pharma Letter - Mar 13 2014]
First reported Dec 05 2013 - Updated Dec 05 2013 - 1 reports

Decision Resources says increasing use of Allerganâs Botox & new nontriptan products launch will boost migraine market growth through 2022

Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that the use of Allergan’s Botox for the prophylactic treatment of chronic migraine will increase modestly in the major pharmaceutical ... [Published PharmaBiz - Dec 05 2013]
First reported Oct 23 2013 - Updated Oct 23 2013 - 1 reports

CoLucid, Ildong sign distribution agreement for acute migraine agent

US-based CoLucid Pharmaceuticals and South Korean Ildong Pharmaceutica have signed a distribution and supply agreement for Lasmiditan, a new agent for acute migraine, in South Korea and Southeast Asia.Pursuant to the terms of the agreement, CoLucid will ... [Published Pharmaceutical Business Review - Oct 23 2013]

Quotes

...developed under its partnership and be subsequently well positioned to perform in the Korean market and Southeast Asia in the near future. "We are sure that this will provide us a further opportunity to strengthen the relationship between our two companies" Lee added. CoLucid has successfully completed six clinical studies, including Phase IIb study and TQTc study, for Lasmiditan
ILDONG Pharma Chairman and CEO, Jung-chi Lee, Ph D , commented, "We expect CoLucid's innovative drug, Lasmiditan, to be successfully developed under our partnership and be subsequently well positioned to perform in the Korean market and Southeast Asia"

More Content

All (5) | News (4) | Reports (0) | Blogs (0) | Audio/Video (0) | Fact Sheets (0) | Press Releases (1)
sort by: Date | Relevance
New Market Research Report: Alzheimer's Disease... [Published SBWire - Apr 15 2014]
Modest growth forecast for global migraine mark... [Published Pharma Letter - Mar 13 2014]
Decision Resources says increasing use of Aller... [Published PharmaBiz - Dec 05 2013]
CoLucid, Ildong sign distribution agreement for... [Published Pharmaceutical Business Review - Oct 23 2013]
CoLucid Pharmaceuticals and ILDONG Pharmaceutic... [Published PR Newswire - Oct 23 2013]
1
Content Volume
Document Volume
Network
Network

Press Releases

sort by: Date | Relevance
CoLucid Pharmaceuticals and ILDONG Pharmaceutic... [Published PR Newswire - Oct 23 2013]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.